We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Days After BsUFA III Reauthorization, FDA Launches Biosimilar Regulatory Pilot Program
Days After BsUFA III Reauthorization, FDA Launches Biosimilar Regulatory Pilot Program
Just days after Congress reauthorized the third iteration of the biosimilar user fee act, BsUFA III, the FDA has announced that it’s launching a pilot program to improve the efficiency of biosimilar product development and advance the development of interchangeable products.